NBIX vs. RVTY: Neurocrine Biosciences vs. Revvity Stock Comparison

November 11, 2026

How do Neurocrine Biosciences (NBIX) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Neurocrine Biosciences (NBIX) and Revvity (RVTY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NBIX is classified in Biotechnology while RVTY is classified in Life Sciences Tools & Services.

Company profile comparison for Neurocrine Biosciences (NBIX) and Revvity (RVTY)
Profile Item	NBIX	RVTY
Name	Neurocrine Biosciences, Inc.	Revvity Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	16.66 billion USD	17.31 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	May 23, 1996	February 21, 1973
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

NBIX

RVTY

GSPC

Neurocrine Biosciences (NBIX) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Neurocrine Biosciences (NBIX) and Revvity (RVTY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Neurocrine Biosciences (NBIX) and Revvity (RVTY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Neurocrine Biosciences (NBIX) and Revvity (RVTY)
Metric	NBIX	RVTY
Total Return (1Y)	9.40%	76.75%
Total Return (3Y, Annualized)	14.12%	24.22%
Total Return (5Y, Annualized)	12.61%	-1.48%

Risk Profile

Drawdown History

NBIX

RVTY

GSPC

Neurocrine Biosciences (NBIX) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Neurocrine Biosciences (NBIX) and Revvity (RVTY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Neurocrine Biosciences (NBIX) and Revvity (RVTY)
Metric	NBIX	RVTY
Volatility (1Y, Annualized)	35.05%	40.22%
Beta (5Y)	0.29	1.07
Max Drawdown (5Y)	-42.89%	-59.01%
Avg. Volume (3M)	1.31M	1.89M

Risk-Adjusted Performance

Risk-Return Positioning

NBIX and RVTY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Neurocrine Biosciences (NBIX) and Revvity (RVTY)
Metric	NBIX	RVTY
Sharpe Ratio (1Y)	0.15	1.80
Sortino Ratio (1Y)	0.22	2.90

Profitability

ROE (TTM)

Neurocrine Biosciences (NBIX) at 20.42% sits in the top ROE quartile, while Revvity (RVTY) at 3.45% is closer to the peer norm — stronger capital efficiency for NBIX.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.42%

Max: 109.18%
NBIX: 20.42%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max: 109.18%
Q3: 6.23%
RVTY: 3.45%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Neurocrine Biosciences (NBIX) vs. Revvity (RVTY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Neurocrine Biosciences (NBIX) at 18.98% keeps the most of each sales dollar — above its industry’s net margin range — and Revvity (RVTY) at 8.61% also retains a top-quartile share.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.98%

NBIX: 18.98%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max: 18.05%
RVTY: 8.61%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Neurocrine Biosciences (NBIX) vs. Revvity (RVTY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Neurocrine Biosciences (NBIX) at 31.98% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.98%

Max: 83.12%
NBIX: 31.98%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max: 83.12%
RVTY: 17.06%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Neurocrine Biosciences (NBIX) vs. Revvity (RVTY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Neurocrine Biosciences (NBIX) and Revvity (RVTY)
Metric	NBIX	RVTY
ROE (TTM)	20.42%	3.45%
ROA (TTM)	12.45%	2.54%
Net Margin (TTM)	18.98%	8.61%
Operating Margin (TTM)	31.98%	17.06%
Gross Margin (TTM)	64.67%	55.91%

Growth

Revenue Growth

Both Neurocrine Biosciences (NBIX) at 21.45% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Neurocrine Biosciences (NBIX) vs. Revvity (RVTY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Neurocrine Biosciences (NBIX) at 41.95% and Revvity (RVTY) at -5.91% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Neurocrine Biosciences (NBIX) vs. Revvity (RVTY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Neurocrine Biosciences (NBIX) and Revvity (RVTY)
Metric	NBIX	RVTY
Revenue Growth (YoY)	21.45%	3.67%
Revenue Growth (3Y CAGR)	24.32%	-4.82%
EPS Growth (YoY)	41.95%	-5.91%
EPS Growth (3Y CAGR)	44.12%	-23.26%

Financial Strength

Current Ratio (MRQ)

Revvity (RVTY) at 2.65 keeps current ratio within its industry’s typical mid-range, while Neurocrine Biosciences (NBIX) at 2.04 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NBIX.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.04

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
NBIX: 2.04
Min: 0.10

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max: 25.13
Q3: 12.13
Median: 5.52
RVTY: 2.65
Q1: 2.47
Min: 0.10

Neurocrine Biosciences (NBIX) vs. Revvity (RVTY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Neurocrine Biosciences (NBIX) at 0.12 and Revvity (RVTY) at 0.38 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.12

Max: 1.42
Q3: 0.65
Median: 0.15
NBIX: 0.12
Q1: 0.02
Min: 0.00

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max: 1.42
Q3: 0.65
RVTY: 0.38
Median: 0.15
Q1: 0.02
Min: 0.00

Neurocrine Biosciences (NBIX) vs. Revvity (RVTY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Neurocrine Biosciences (NBIX) and Revvity (RVTY)
Metric	NBIX	RVTY
Current Ratio (MRQ)	2.04	2.65
Debt / Equity (MRQ)	0.12	0.38
Net Debt / EBITDA	-0.27	2.43

Dividends

Dividend Yield (TTM)

Neurocrine Biosciences (NBIX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

NBIX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY: 0.19%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Neurocrine Biosciences (NBIX) vs. Revvity (RVTY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neurocrine Biosciences (NBIX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

NBIX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY: 13.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Neurocrine Biosciences (NBIX) vs. Revvity (RVTY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Neurocrine Biosciences (NBIX) and Revvity (RVTY)
Metric	NBIX	RVTY
Dividend Yield (TTM)	0.00%	0.19%
Dividend Payout Ratio (TTM)	0.00%	13.40%

Valuation

P/E Ratio (TTM)

Neurocrine Biosciences (NBIX) at 24.43 is near its industry’s usual P/E ratio, while Revvity (RVTY) at 68.94 sits in the richer quartile — RVTY needs stronger growth or earnings quality to justify the premium.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.43

Max: 85.34
Q3: 43.46
Median: 26.69
NBIX: 24.43
Q1: 13.30
Min: 0.07

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max: 85.34
RVTY: 68.94
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Neurocrine Biosciences (NBIX) vs. Revvity (RVTY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Neurocrine Biosciences (NBIX) at 4.50 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.50

Max: 58.18
Q3: 25.77
Median: 7.30
NBIX: 4.50
Q1: 3.01
Min: 0.01

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max: 58.18
Q3: 25.77
Median: 7.30
RVTY: 5.88
Q1: 3.01
Min: 0.01

Neurocrine Biosciences (NBIX) vs. Revvity (RVTY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Neurocrine Biosciences (NBIX) at 4.30 and Revvity (RVTY) at 2.39 are valued close to their industries’ norm against book — neither stands out from peers.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.30

Max: 13.53
Q3: 6.54
NBIX: 4.30
Median: 3.25
Q1: 1.69
Min: -5.59

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max: 13.53
Q3: 6.54
Median: 3.25
RVTY: 2.39
Q1: 1.69
Min: -5.59

Neurocrine Biosciences (NBIX) vs. Revvity (RVTY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Neurocrine Biosciences (NBIX) and Revvity (RVTY)
Metric	NBIX	RVTY
P/E Ratio (TTM)	24.43	68.94
P/S Ratio (TTM)	4.50	5.88
P/B Ratio (MRQ)	4.30	2.39
Free Cash Flow Yield (TTM)	6.11%	3.62%